Camptothecins Compared With Etoposide In Combination With Platinum Analog In Extensive Stage Small Cell Lung Cancer: Systematic Review With Meta-analysis

Superiority of camptothecin regimens over etoposide-both combined with platinum analogs-in extensive disease small cell lung cancer has been a matter of debate with contradictory findings in randomized trials. A systematic review was sought to elucidate this issue. Methods: Randomized controlled trials comparing first-line camptothecin-platinum doublets versus etoposide-platinum doublets in patients with extensive disease small cell lung cancer were searched in MEDLINE, EMBASE, LILACS, and CENTRAL databases, European Society of Medical Oncology, American Society of Clinical Oncology, and International Association for the Study of Lung Cancer meeting sites. Meta-analyses were performed using fixed-effects model. Subgroup analyses were undertaken comparing each type of camptothecin to etoposide-based regimens. The outcomes of interest were overall survival (OS), progression-free survival (PFS), response rate (RR), and toxicities. Results: Eight studies (3086 patients) were included. The meta-analysis of topotecan regimens (TP) was not reliable due to impending heterogeneity. Meta-analysis of trials testing irinotecan combinations (IP) versus etoposide regimens (EP; 1561 patients) stated an OS improvement in favor of IP arm, though with considerable heterogeneity, whose origin seemed to be a Japanese trial. In the analyses without that study (1407 patients left), IP brought a significant improvement in OS (hazard ratio = 0.87; 95% confidence interval 0.78-0.97; p = 0.02; I 2 = 0). IP also increased PFS (hazard ratio = 0.83; 95% confidence interval 0.73-0.95; p = 0.006; I 2 = 0%). There was no impact in RR (absolute RR 56% with IP; 53% with EP; p = 0.17). IP caused more diarrhea (p < 0.0001) but less hematological toxicities (p < 0.001) than EP. Conclusions: The present meta-analysis demonstrates statistically significant OS and PFS benefits of IP over EP regimens in western and eastern patients. Specific characteristics of safety profile should be taken into account when administrating IP chemotherapy. Copyright © 2010 by the International Association for the Study of Lung Cancer.51219861993Parkin, D.M., Bray, F., Ferlay, J., Global cancer statistics 2002 (2005) CA Cancer J. Clin., 55, pp. 74-108Lara Jr., P.N., Natale, R., Crowley, J., Phase III trial of irinotecan/ cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: Clinical and pharmacogenomic results from SWOG S0124 (2009) J. Clin. Oncol., 27, pp. 2530-2535Govindan, R., Page, N., Morgensztern, D., Read, W., Tierney, R., Vlahiotis, A., Spitznagel, E.L., Piccirillo, J., Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database (2006) Journal of Clinical Oncology, 24 (28), pp. 4539-4544. , DOI 10.1200/JCO.2005.04.4859Lorigan, P., Woll, P.J., O'Brien, M.E.R., Ashcroft, L.F., Sampson, M.R., Thatcher, N., Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer (2005) Journal of the National Cancer Institute, 97 (9), pp. 666-674. , DOI 10.1093/jnci/dji114Chute, J.P., Chen, T., Feigal, E., Simon, R., Johnson, B.E., Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: Perceptible progress (1999) Journal of Clinical Oncology, 17 (6), pp. 1794-1801Jones, D., Klementich, V.F.L.R., Phase II trial of Docetaxel and carboplatin in patients with newly diagnosed extensive-stage small cell carcinoma of the lung SCLC (2005) J. Clin. Oncol., 23. , Abstract 7346Gridelli, C., Perrone, F., Ianniello, G.P., Brancaccio, L., Iaffaioli, R.V., Curcio, C., D'Aprile, M., Bianco, A.R., Carboplatin plus vinorelbine, a new well-tolerated and active regimen for the treatment of extensive-stage small-cell lung cancer: A phase II study (1998) Journal of Clinical Oncology, 16 (4), pp. 1414-1419Dimitroulis, J., Rapti, A., Stathopoulos, G.P., Comparison of cisplatinpaclitaxel combination versus cisplatin-etoposide in patients with smallcell lung cancer: A phase III study (2008) Oncol. Rep., 20, pp. 879-884Mavroudis, D., Papadakis, E., Veslemes, M., Tsiafaki, X., Stavrakakis, J., Kouroussis, C., Kakolyris, S., Georgoulias, V., A multicenter randomized clinical trial comparing paclitaxel-cisplatin- etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer (2001) Annals of Oncology, 12 (4), pp. 463-470. , DOI 10.1023/A:1011131303391Niell, H.B., Herndon II, J.E., Miller, A.A., Watson, D.M., Sandler, A.B., Kelly, K., Marks, R.S., Green, M.R., Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B trial 9732 (2005) Journal of Clinical Oncology, 23 (16), pp. 3752-3759. , DOI 10.1200/JCO.2005.09.071Socinski, M.A., Smit, E.F., Lorigan, P., Phase III study of pemetrexed plus carboplatin PC versus etoposide plus carboplatin EC in chemonaive patients pts with extensive-stage disease small cell lung cancer ED-SCLC: Interim results (2008) ASCO Meeting Category Lung Cancer Local-Regional and Adjuvant Therapy Abs NSANegoro, S., Fukuoka, M., Niitani, H., A phase II study of CPT-11 a camptothecin derivative in patients with primary lung cancer CPT-11 cooperative study group (1991) Gan. To Kagaku. Ryoho., 18, pp. 1013-1019Rocha-Lima, C.M., Herndon III, J.E., Lee, M.E., Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and leukemia group B study 39902 (2007) Ann. Oncol., 18, pp. 331-337Masuda, N., Fukuoka, M., Kusunoki, Y., CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer (1992) J. Clin. Oncol., 10, pp. 1225-1229Noda, K., Nishiwaki, Y., Kawahara, M., Negoro, S., Sugiura, T., Yokoyama, A., Fukuoka, M., Saijo, N., Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer (2002) New England Journal of Medicine, 346 (2), pp. 85-91. , DOI 10.1056/NEJMoa003034Hanna, N., Bunn Jr., P.A., Langer, C., Einhorn, L., Guthrie Jr., T., Beck, T., Ansari, R., Sandler, A., Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lime cancer (2006) Journal of Clinical Oncology, 24 (13), pp. 2038-2043. , DOI 10.1200/JCO.2005.04.8595Hermes, A., Bergman, B., Bremnes, R., Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: A randomized phase III trial (2008) J. Clin. Oncol., 26, pp. 4261-4267Sørensen, M., Felip, E., ESMO guidelines working group small-cell lung cancer: ESMO clinical recommendations for diagnosis treatment and follow-up (2008) Ann. Oncol., pp. ii41-ii42Kalemkerian, G.P., Akerley, W., Downey, R.J., Ettinger, D.S., Fossella, F., Grecula, J.C., Jahan, T., Williams Jr., C.C., Small cell lung cancer (2008) JNCCN Journal of the National Comprehensive Cancer Network, 6 (3), pp. 294-314Eckardt, J.R., Von Pawel, J., Papai, Z., Tomova, A., Tzekova, V., Crofts, T.E., Brannon, S., Ross, G., Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer (2006) Journal of Clinical Oncology, 24 (13), pp. 2044-2051. , DOI 10.1200/JCO.2005.03.3332Moher, D., Cook, D.J., Eastwood, S., Improving the quality of reports of meta-analyses of randomised controlled trials: The quorom statement quality of reporting of meta-analyses (1999) Lancet, 354, pp. 1896-1900Parmar, M.K.B., Torri, V., Stewart, L., Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints (1998) Statistics in Medicine, 17 (24), pp. 2815-2834. , DOI 10.1002/(SICI)1097-0258(19981230)17:243.0. CO;2-8Tierney, J.F., Stewart, L.A., Ghersi, D., Burdett, S., Sydes, M.R., Practical methods for incorporating summary time-to-event data into meta-analysis (2007) Trials, 8, p. 16. , DOI 10.1186/1745-6215-8-16Sterne, J.A.C., Egger, M., Smith, G.D., Investigating and dealing with publication and other biases (2001) Systematic Reviews in Health Care: Metaanalysis in Context, pp. 189-210. , In M Egger, GD Smith, DG Altman (Eds 2nd Ed. London: BMJ Publication GroupDerSimonian, R., Laird, N., Meta-analysis in clinical trials (1986) Controlled Clinical Trials, 7 (3), pp. 177-188. , DOI 10.1016/0197-2456(86)90046-2Higgins, J.P., Thompson, S.G., Deeks, J.J., Measuring inconsistency in meta-analyses (2003) BMJ, 327, pp. 557-560Seiter, K., Toxicity of the topoisomerase I inhibitors (2005) Expert Opin. Drug. Saf., 4, pp. 45-53Hartmann, J.T., Lipp, H.P., Camptothecin and podophyllotoxin derivatives: Inhibitors of topoisomerase I and II-mechanisms of action pharmacokinetics and toxicity profile (2006) Drug. Saf., 29, pp. 209-230Pan, D., Hou, M., Li, H., Yu, P., Liu, J., Irinotecan plus cisplatin compared with etoposide plus cisplatin for small cell lung cancer: A randomized clinical trial (2006) Chinese Journal of Lung Cancer, 9 (5), pp. 443-446Heigener, D.F., Freitag, L., Eschbach, C., Topotecan/cisplatin TP compared to cisplatin/etoposide PE for patients with extensive diseasesmall cell lung cancer ED-SCLC: Final results of a randomised phase III trial (2008) J. Clin. Oncol., 26. , bstract 7513Zhang, S., Wang, J., Wang, Q., Zhang, H., Hu, F., Yang, X., Fan, X., Li, Xi., A randomized study comparing topotecan plus cisplatin versus etoposide plus carboplatin for previously untreated small cell lung cancer (2007) Chinese Journal of Lung Cancer, 10 (2), pp. 144-147Schmittel, A.H., Sebastian, M., Fischer Von Weikersthal, L., Irinotecan plus carboplatin versus etoposide plus carboplatin in extensive disease small cell lung cancer: Results of the German randomized phase III trial (2009) J. Clin. Oncol., 27. , Abstract 8029Natale, R.B., Lara, P.N., Chansky, K., S0124: A randomized phase III trial comparing irinotecan/cisplatin IP with etoposide/cisplatin EP in patients pts with previously untreated extensive stage small cell lung cancer E-SCLC (2008) J. Clin. Oncol., 26. , Abstract 7512Eckardt, J.R., Von Pawel, J., Pujol, J.-L., Papai, Z., Quoix, E., Ardizzoni, A., Poulin, R., Ross, G., Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer (2007) Journal of Clinical Oncology, 25 (15), pp. 2086-2092. , DOI 10.1200/JCO.2006.08.3998Ardizzoni, A., Manegold, C., Debruyne, C., Gaafar, R., Buchholz, E., Smit, E.F., Lianes, P., Giaccone, G., European Organization for Research and Treatment of Cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer (2003) Clinical Cancer Research, 9 (I1), pp. 143-150Naka, N., Kawahara, M., Okishio, K., Hosoe, S., Ogawara, M., Atagi, S., Takemoto, Y., Furuse, K., Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer (2002) Lung Cancer, 37 (3), pp. 319-323. , DOI 10.1016/S0169-5002(02)00073-9, PII S0169500202000739Hirose, T., Horichi, N., Ohmori, T., Ogura, K., Hosaka, T., Ando, K., Ishida, H., Adachi, M., Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer (2003) Lung Cancer, 40 (3), pp. 333-338. , DOI 10.1016/S0169-5002(03)00075-8Takigawa, N., Fujiwara, K., Ueoka, H., Kiura, K., Tabata, M., Hiraki, A., Shibayama, T., Harada, M., Fractionated administration of irinotecan and cisplatin for treatment of extensive-disease small-cell lung cancer: A phase II study (2003) Anticancer Research, 23 (B1), pp. 557-560Ioannidis, J.P., Interpretation of tests of heterogeneity and bias in metaanalysis (2008) J. Eval. Clin. Pract., 14, pp. 951-957Hande, K., Messenger, M., Wagner, J., Krozely, M., Kaul, S., Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration (1999) Clinical Cancer Research, 5 (10), pp. 2742-2747Hande, K.R., Krozely, M.G., Greco, F.A., Bioavailability of low-dose oral etoposide (1993) J. Clin. Oncol., 11, pp. 374-377Hotta, K., Kiura, K., Fujiwara, Y., Association between incremental gains in the objective response rate and survival improvement in phase III trials of first-line chemotherapy for extensive disease small-cell lung cancer (2009) Ann. Oncol., 20, pp. 829-834Yao, N., Jiang, L., Yang, K., Irinotecan/cisplatin versus etoposide/cisplatin for patients with extensive stage small cell lung cancer: A systematic review (2009) Chin. J. Lung. Cancer, 12, pp. 884-88